Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (rHGH, Insulin, Interferon), Glycosylated (EPO, mAb), Peptides (Calcitonin, Glucagon)), Manufacturing Type (Contract, In-house), Disease (Autoimmune, Oncology) – 2019 to 2024

$3,850.00$5,850.00

AVAIL 20% DISCOUNT ON PURCHASE OF ANY REPORT
Published on: June 2, 2019
Clear
SKU: GMS815 Category:

The market for biosimilars is expected to reach USD 25.12 billion by 2024, rising at a CAGR of 29.2% during the forecast period. Market growth is driven primarily by increasing demand for biosimilar drugs due to their cost-effectiveness, increasing incidences of chronic diseases, and strategic collaborations resulting in increased productivity and clinical trial activities.

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (rHGH, Insulin, Interferon), Glycosylated (EPO, mAb), Peptides (Calcitonin, Glucagon)), Manufacturing Type (Contract, In-house), Disease (Autoimmune, Oncology) - 2019 to 2024 1

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (rHGH, Insulin, Interferon), Glycosylated (EPO, mAb), Peptides (Calcitonin, Glucagon)), Manufacturing Type (Contract, In-house), Disease (Autoimmune, Oncology) - 2019 to 2024 2

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (rHGH, Insulin, Interferon), Glycosylated (EPO, mAb), Peptides (Calcitonin, Glucagon)), Manufacturing Type (Contract, In-house), Disease (Autoimmune, Oncology) - 2019 to 2024 3

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (rHGH, Insulin, Interferon), Glycosylated (EPO, mAb), Peptides (Calcitonin, Glucagon)), Manufacturing Type (Contract, In-house), Disease (Autoimmune, Oncology) - 2019 to 2024 4

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (rHGH, Insulin, Interferon), Glycosylated (EPO, mAb), Peptides (Calcitonin, Glucagon)), Manufacturing Type (Contract, In-house), Disease (Autoimmune, Oncology) - 2019 to 2024 5

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (rHGH, Insulin, Interferon), Glycosylated (EPO, mAb), Peptides (Calcitonin, Glucagon)), Manufacturing Type (Contract, In-house), Disease (Autoimmune, Oncology) - 2019 to 2024 6

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (rHGH, Insulin, Interferon), Glycosylated (EPO, mAb), Peptides (Calcitonin, Glucagon)), Manufacturing Type (Contract, In-house), Disease (Autoimmune, Oncology) - 2019 to 2024 7

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (rHGH, Insulin, Interferon), Glycosylated (EPO, mAb), Peptides (Calcitonin, Glucagon)), Manufacturing Type (Contract, In-house), Disease (Autoimmune, Oncology) - 2019 to 2024 8

1 Global Biosimilars Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 Global Biosimilars Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 Global Biosimilars Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 Global Biosimilars Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 Global Biosimilars Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 Global Biosimilars Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 Global Biosimilars Market – By Product (Market Size – & million/billion)
8.1 Recombinant Non-glycosylated Proteins
8.2 Recombinant Glycosylated Proteins
8.3 Recombinant Peptides

9 Global Biosimilars Market – By Type of Manufacturing
9.1 In-house Manufacturing
9.2 Contract Manufacturing

10 Global Biosimilars Market – By Disease
10.1 Oncology
10.2 Blood Disorders
10.3 Chronic Diseases
10.4 Autoimmune Diseases
10.5 Growth Hormone Deficiency
10.6 Infectious Diseases
10.7 Other Diseases

11 Global Biosimilars Market – By Geography (Market Size – & million/billion)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 U.K
11.3.2 Germany
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Rest of APAC
11.5 Rest of the World
11.5.1 South America
11.5.2 Middle East
11.5.3 Africa

12 Global Biosimilars Market – Entropy
12.1 New product launches
12.2 M&A’s, collaborations, JVs and partnerships

13 Global Biosimilars Market Company Profile (Key Players)
13.1 Market Share, Company Revenue, Products, M&A, Developments
13.2 Sandoz
13.3 Samsung Biologics
13.4 Pfizer
13.5 Mylan
13.6 Dr. Reddy’s Laboratories
13.7 Stada Arzneimittel AG
13.8 Celltrion
13.9 Teva Pahrmaceutical
13.10 Biocon
13.11 Amgen
13.12 Company 11 & more

14 Global Biosimilars Market – Appendix
14.1 Sources
14.2 Abbreviations